A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5

Amyloid

Volumn 20, Issue 1, 2013, Pages 21-26

  Wall, Jonathan S ^a   Richey, Tina ^a   Macy, Sally ^a   Heidel, Eric ^b   Wooliver, Craig ^a   Kennel, Stephen J ^a  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

AA amyloid; Biodistribution; Congo red; Peptides; Tissue amyloid

Indexed keywords

AMYLOID A PROTEIN; CONGO RED; IODINE 125;

AMYLOIDOSIS; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BIREFRINGENCE; ISOTOPE LABELING; LIVER; MALE; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOIODINATION; SPLEEN;

AMINO ACID SEQUENCE; AMYLOID; AMYLOIDOSIS; ANIMALS; IODINE RADIOISOTOPES; LIVER; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; SPLEEN;

EID: 84874135284     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2012.757216     Document Type: Article

References (30)

1. Lachmann H J, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol 2006;6:214-20 (Pubitemid 43362138)
2. Pepys MB. Amyloidosis. Annu Rev Med 2006;57:223-41 (Pubitemid 43261989)
3. Hawkins P N, Pepys MB. Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med 1995;22:595-9
4. Hazenberg B P, van Rijswijk M H, Piers D A, Lub-de Hooge MN, Vellenga E, Haagsma E B, Hawkins P N, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006;119:355 e315-24
5. Wall J S, Kennel S J, Paulus M J, Gleason S, Gregor J, Baba J, Schell M, et al. Quantitative High-Resolution Microradiographic Imaging of Amyloid Deposits in a Novel Murine Model of AAAmyloidosis. Amyloid 2005;12:146-51
6. Wall J S, Kennel S J, Stuckey A C, Long M J, Townsend D W, Smith GT, Wells K J, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 2010;116:2241-4
7. Wall J S, Richey T, Stuckey A, Donnell R, Macy S, Martin EB, Williams A, et al. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl Acad Sci U S A 2011;108:E586-94
8. Hawkins P N, Lavender J P, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508-13 (Pubitemid 20260051)
9. Townsend DW. Positron emission tomography/computed tomography. Semin Nucl Med 2008;38:152-66 (Pubitemid 351466916)
10. Townsend DW. Multimodality imaging of structure and function. Phys Med Biol 2008;53:R1-39 (Pubitemid 351238134)
11. Lois C, Jakoby B W, Long M J, Hubner K F, Barker D W, Casey ME, Conti M, et al. An assessment of the impact of incorporating timeof-flight information into clinical PET/CT imaging. J Nucl Med 2010;51:237-45
12. Lindahl B, Lindahl U. Amyloid-specific heparan sulfate from human liver and spleen. J Biol Chem 1997;272:26091-4 (Pubitemid 27458814)
13. Smits N C, Kurup S, Rops A L, ten Dam G B, Massuger LF, Hafmans T, Turnbull J E, et al. The heparan sulfate motif (GlcNS6S-IdoA2S)3, common in heparin, has a strict topography and is involved in cell behavior and disease. J Biol Chem 2010;285:41143-51
14. Zhang X, Li JP. Heparan sulfate proteoglycans in amyloidosis. Prog Mol Biol Transl Sci 2010;93:309-34
15. Wall J S, Richey T, Williams A, Stuckey A, Osborne D, Martin E, Kennel SJ. Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT. Mol Imaging Biol. 2012;14:402-7
16. Solomon A, Weiss D T, Schell M, Hrncic R, Murphy C L, Wall J, McGavin M D, et al. Transgenic mouse model of AA amyloidosis. Am J Pathol 1999;154:1267-72 (Pubitemid 29169760)
17. Wall J S, Richey T, Allen A, Donnell R, Kennel S J, Solomon A. Quantitative tomography of early-onset spontaneous AA amyloidosis in interleukin 6 transgenic mice. Comp Med 2008;58:542-50
18. Ailles L, Kisilevsky R, Young ID. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab Invest 1993;69:443-8 (Pubitemid 23335844)
19. Axelrad M A, Kisilevsky R, Willmer J, Chen S J, Skinner M. Further characterization of amyloid-enhancing factor. Lab Invest 1982;47:139-46 (Pubitemid 12051536)
20. Wall J S, Paulus M J, GLeason S, Gregor J, Solomon A, Kennel SJ. Micro-imaging of Amyloid in Mice. Meth Enzymol 2006;412:161-82 (Pubitemid 44548580)
21. Villemagne V L, Rowe CC. Amyloid imaging. Int Psychogeriatr 2011;23:S41-9
22. Mathis C A, Mason N S, Lopresti B J, Klunk WE. Development of positron emission tomography beta-Amyloid plaque imaging agents. Semin Nucl Med 2012;42:423-32
23. Kung M P, Weng C C, Lin K J, Hsiao I T, Yen T C, Wey SP. Amyloid plaque imaging from IMPY/SPECT to AV-45/PET. Chang Gung Med J 2012;35:211-8
24. Doraiswamy P M, Sperling R A, Coleman R E, Johnson K A, Reiman EM, Davis M D, Grundman M, et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: B multicenter study. Neurology 2012;79:1636-44
25. Newberg A B, Arnold S E, Wintering N, Rovner B W, Alavi A. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med 2012;53:902-7
26. Clark C M, Schneider J A, Bedell B J, Beach T G, Bilker W B, Mintun MA, Pontecorvo M J, et al. Use of florbetapir-PET for imaging betaamyloid pathology. JAMA 2011;305:275-83
27. Basu S, Kwee T C, Surti S, Akin E A, Yoo D, Alavi A. Fundamentals of PET and PET/CT imaging. Ann N Y Acad Sci 2011;1228:1-18
28. Newkirk K M, Newman S J, White L A, Rohrbach B W, Ramsay EC. Renal lesions of nondomestic felids. Vet Pathol 2011;48:698-705
29. Chew D J, DiBartola S P, Boyce J T, Gasper PW. Renal amyloidosis in related Abyssinian cats. J Am Vet Med Assoc 1982;181:139-42 (Pubitemid 12042595)
30. Martin E, Kennel S, Richey T, Stuckey A, Osborne D, Wall J. The peptide p5 binds rapidly to vicseral amyloid in vivo and persists for more than 72 h rendering it suitable for PET/CT imaging using I124. J Nuc Med 2012;53:336